Neurocrine spent the second quarter proving it is no longer just an INGREZZA company, and the market is still deciding whether that transformation justifies the cash it consumed. The May completion of the Soleno Therapeutics purchase added VYKAT XR, a first-in-class treatment for the relentless hunger of Prader-Willi syndrome, to a commercial roster that already includes the movement-disorder franchise and CRENESSITY for classic congenital adrenal hyperplasia. Management paid $53 per share in an all-cash tender. Kyle Gano framed the print as a strategy designed to compound. The more honest read is that the company just spent its fortress balance sheet to buy time against a Medicare negotiation clock on the original franchise.
The income statement shows why the stock sold off after a beat. Total second-quarter revenue reached $959 million. Operating income barely moved despite that lift. Selling, general, and administrative expense jumped as the company staffed two launches and absorbed deal costs, while research spending climbed to support late-stage programs in depression and schizophrenia. Cash and marketable securities fell to $482 million after the all-cash close. The year-end starting point sat above $2 billion. The operating engine is still throwing off cash at a healthy clip. The balance sheet is now thin by Neurocrine standards.
The next year answers a narrower question than the pipeline calendar implies. Can CRENESSITY and VYKAT XR keep taking share of the mix so that INGREZZA is no longer the overwhelming majority of product sales by the time Inflation Reduction Act negotiation arrives? If the two newer brands stall, the Soleno check looks like an expensive detour. If they scale, the equity is a three-franchise rare-disease platform trading as if the second and third products still need to prove they exist.